Drugs / LY01011
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04198636 | Dec 2019 → Dec 2020 | — | Luye Pharma Group Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04859569 | Apr 2021 → Dec 2022 | metastatic carcinoma in the bone | Luye Pharma Group Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY01011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04859569 ↗ |
| Action | Inhibit | “recombinant anti-RANKL human monoclonal antibody injection” NCT04859569 ↗ |
| Modality | Monoclonal antibody | “recombinant anti-RANKL human monoclonal antibody injection” NCT04859569 ↗ |
| Route | Subcutaneous | “by subcutaneous injection” NCT04198636 ↗ |